Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Am J Obstet Gynecol. 2007 Mar;196(3):219.e1-7.

Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate.

Author information

  • 1Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, MetroHealth Medical Center, Cleveland, OH, USA.

Abstract

OBJECTIVE:

This study was undertaken to assess the impact of 17 alpha hydroxyprogesterone caproate treatment on future medical costs for expectant mothers with a prior spontaneous preterm birth.

STUDY DESIGN:

Data on the costs of preterm birth were combined with published data on the effectiveness of 17 alpha hydroxyprogesterone caproate to produce estimates of the effect of treatment on expected future direct medical costs. These estimates were compared with an estimate of the cost of a typical 17 alpha hydroxyprogesterone caproate treatment regimen to estimate the net savings per treated woman.

RESULTS:

Treatment is estimated to reduce initial neonatal hospitalization costs by 3800 dollars per woman treated with 17 alpha hydroxyprogesterone caproate. Expected lifetime medical costs (discounted) of treated infants are estimated to decline 15,900 dollars.

CONCLUSIONS:

Treating expectant mothers with a prior spontaneous preterm birth with 17 alpha hydroxyprogesterone caproate generates future medical cost savings that substantially exceed the cost of treatment. If this population were universally treated with 17 alpha hydroxyprogesterone caproate, discounted lifetime medical costs of their offspring could be reduced by more than 2.0 billion dollars annually.

Comment in

PMID:
17346527
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk